Company Information

Learn More About XBRL  

Address: 6725 MESA RIDGE ROAD
SUITE 100 
City: SAN DIEGO 
State: CA 
Zip Code: 92131 
Telephone: 858-552-0866 


Description of Business


Primary SIC Code: 2834
(As filed with the SEC)  

We are a development-stage specialty pharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates for the treatment of cancer. We seek to improve the performance of existing drugs by addressing limitations associated principally with their safety and use. We have not yet marketed or sold any products or generated any significant revenue. Our lead product candidates, ANX-530 (vinorelbine injectable emulsion) and ANX-514 (docetaxel injectable emulsion), are novel emulsion formulations of currently marketed chemotherapy drugs. We believe ANX-530 and ANX-514 may improve the safety of and have greater commercial potential than the currently marketed reference products, Navelbine® (vinorelbine tartrate) Injection and Taxotere® (docetaxel) Injection Concentrate, respectively, by: . reducing the incidence and severity of adverse effects; and .  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2010-2.46NAN/E
03/2010-77.75NAN/E
12/2009-87.50NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2009 Leverage 2009
Net Inc/Comm Equity-0.08Total Liab/Total Assets0.26
Net Inc/Total Assets-1.25Total Liab/Inv Cap0.35
Net Inc/Inv Cap-1.70Total Liab/Comm Equity0.02
Pretax Inc/Net Sales-37.75Interest Coverage RatioNA
Net Inc/Net Sales-37.75Curr Debt/EquityNA
Cash Flow/Net Sales-42.05LTD/EquityNA
SG&A/NetSales16.66Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover4.39Quick Ratio3.81
Inventory TurnoverNACurrent Ratio3.81
Inventory Day SalesNANet Rec/Curr Assets0.00
Net Sales/Work Cap0.05Inv/Curr AssetsNA
Net Sales/PP&E6.79  

Income Statement (Millions)

  6/30/2010 3/31/2010 12/31/2009 9/30/2009
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold 0.00 0.00 0.00 0.00
Selling & Admin Exps 1.30 1.17 1.25 0.89
Operating Income -1.94 -2.42 -3.22 -2.35
Interest Exp 0.00 0.00 0.00 0.00
Pretax Income -1.92 -2.40 -3.22 -2.35
Other Income 0.02 0.02 0.00 -0.00
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.92 -2.40 -3.22 -2.35

Balance Sheet (Millions)

Assets 6/30/2010 3/31/2010 12/31/2009 9/30/2009
Cash & Short Term Investments 31.79 19.81 8.67 3.16
Receivables - Total 0.01 0.01 0.01 0.04
Inventories - Total NA NA NA NA
Total Current Assets 32.40 20.03 8.97 3.77
Net Property, Plant & Equipment 0.04 0.05 0.04 0.05
Total Assets 32.44 20.07 9.03 3.83
Liabilities        
Accounts Payable 1.33 1.25 2.35 2.21
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 1.96 1.25 2.35 2.21
Long-Term Debt NA NA NA NA
Total Liabilities 1.96 1.25 2.35 2.21
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 2.47 0.00 0.00 0.00
Common Stock 0.01 0.01 0.21 0.12
Retained Earnings -152.00 -146.96 -142.04 -135.56
Treasury Stock NA NA NA NA
Total Stockholders' Equity 30.48 18.83 6.67 1.62
Total Liabilities and Stockholders' Equity 32.44 20.07 9.03 3.83

Cash Flow Summary (Millions)

Categories 6/30/2010 3/31/2010 12/31/2009 9/30/2009
Net Cash Provided by Operating Activities -2.00 -3.18 -2.63 -3.79
Net Cash Provided by Investing Activities 0.00 -0.01 0.00 0.00
Net Cash Provided by Financing Activities 13.34 14.33 8.14 1.53

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20050.50-24.78--
12/20060.00-29.33--
12/20070.50-22.14--
12/20080.50-26.65--
12/20090.30-11.33-87.50
Growth Rates-11.81----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/10272581.76




Report Date : 8/30/2010

Powered By Edgar Online Copyright 2010, EDGAR Online, Inc. All rights reserved. Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.